XYMOGEN Announces New Marketing Director

XYMOGEN Announces New Marketing Director

 

ORLANDO, Fla., Aug. 20, 2013 /PRNewswire/ -- Orlando-based nutraceutical company XYMOGEN announced today that Chris Mason has joined the organization as Marketing Director.

Chris has more than 18 years of management experience and previously served as Director of Operations for a natural healthcare clinic offering innovative care to clients in Phoenix, Ariz. During his time with the health center, he was instrumental in generating sales growth through strategic marketing initiatives and successful community relations tactics.

"As an entrepreneur with a proven track record of success in the healthcare industry, Chris joins the company with years of expertise and experience," said XYMOGEN CEO Brian Blackburn. "I am confident in the innovative changes that his skills and capabilities will bring to the brand's marketing strategy."

Mason plans to leverage his years of managerial, operational and strategic experience to uphold the success of the family-owned company.

"I look forward to contributing to the success of this fast-growing and innovative enterprise. In stepping into the role of Marketing Director, I plan to assist in growing the XYMOGEN brand and to increase sales and visibility for the company."

Mason is currently pursuing a Ph.D. at Capella University in organizational management with a concentration in leadership and ethics. He also holds a Master's of Business Administration from Norwich University and a Bachelor of Arts in business administration from St. Thomas Aquinas College.

About XYMOGEN
XYMOGEN, a family-owned, health sciences company with headquarters in Orlando, Fla., has been providing high-quality dietary supplements to licensed health care practitioners for more than a quarter century.

The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.

XYMOGEN's strength as a company was reinforced in 2007, 2008, 2010, 2011 and 2012 when it was recognized by Inc. Magazine as one of the 5,000 fastest-growing private companies in America.

The company's 136,000-square-foot manufacturing facility is GMP (good manufacturing practices) and GMP for Sport Athletic Banned Substances Program registered by NSF International.

More information is available at www.xymogen.com

Please email [email protected] for comments or inquiries.

Distributed by Sara Brady Public Relations, Inc.
222 W. Comstock Avenue, Suite 215
Winter Park, Florida 32789
407-702-6632
www.sarabradypr.com

For information, contact:
Sara R. Brady
407-702-6632

SOURCE XYMOGEN

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.